Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells

1 Nov 2024

Abstract excerpt

NKG2D ligands (NKG2DLs) are broadly expressed in cancer. To target these, we describe an adaptor chimeric antigen receptor (CAR) termed NKG2D/Dap10-12 . Herein, T cells are engineered to co-express NKG2D with a fusion protein that comprises Dap10 joined to a Dap12 endodomain. NKG2D/Dap10-12 T cells elicit compelling efficacy, eradicating or controlling NKG2DL-expressing tumors in several established xenograft...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39566469
DOI: 10.1016/j.xcrm.2024.101827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Solid tumor immunotherapy using NKG2D-based adaptor CAR T cellsPMID 39566469Read ↗

Recent Progress in NKG2D CAR-NK Cells for Cancer ImmunotherapySemantic proximity Read ↗

DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.Semantic proximity Read ↗

Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancerSemantic proximity Read ↗

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.Semantic proximity Read ↗

KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Semantic proximity Read ↗

Leveraging NKG2D Ligands in Immuno-OncologySemantic proximity Read ↗

NKG2D Receptor and Its Ligands in Host DefenseSemantic proximity Read ↗

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.Semantic proximity Read ↗

SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicitySemantic proximity Read ↗

NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.Semantic proximity Read ↗

Strength in Unity: a Dual Strategy to Restore NK Cell Cytotoxicity against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedsideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.